Nothing Special   »   [go: up one dir, main page]

YU45837B - Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom - Google Patents

Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom

Info

Publication number
YU45837B
YU45837B YU8288A YU8288A YU45837B YU 45837 B YU45837 B YU 45837B YU 8288 A YU8288 A YU 8288A YU 8288 A YU8288 A YU 8288A YU 45837 B YU45837 B YU 45837B
Authority
YU
Yugoslavia
Prior art keywords
nicardipine
cyclodextrin
hydrochloride
beta
procedure
Prior art date
Application number
YU8288A
Other languages
English (en)
Other versions
YU8288A (en
Inventor
B. Husu
J. Milovac
Z. Kopitar
B. Huč
J. Žmitek
P. Bukovec
M. Žorž
B. Rusjakovski
P. Cvelbar
Z. Jerala-Štrukelj
B. Kofler
Original Assignee
LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. filed Critical LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d.
Priority to SI8810082A priority Critical patent/SI8810082A8/sl
Priority to YU8288A priority patent/YU45837B/sh
Priority to DE3854387T priority patent/DE3854387T2/de
Priority to EP88121797A priority patent/EP0324982B1/en
Priority to JP1006075A priority patent/JPH0780849B2/ja
Priority to US07/298,151 priority patent/US5079237A/en
Priority to YU125289A priority patent/YU45850B/sh
Publication of YU8288A publication Critical patent/YU8288A/xx
Publication of YU45837B publication Critical patent/YU45837B/sh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

POSTOPEK ZA PRIPRAVO NOVEGA INKLUZIJSKEGA KOMPLEKSA NIKARDIPINA OZ. NJEGOVEGA HIDROKLORIDA Z BETA-CIKLODEKSTRINOM, označen s tem, da nikardipinu oz. njegovemu hidrokloridu dodamo beta-ciklodekstrin v molskem razmerju obeh komponent 1:0,9-1,1 ob mešanju pri temperaturi od okoli sobne temperature do temperature vrelišča reakcijske zmesi v vodnem ali etanolnem mediju, ohladimo na 0 do 5 C in izoliramo želeni kompleks.
YU8288A 1988-01-18 1988-01-18 Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom YU45837B (sh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SI8810082A SI8810082A8 (en) 1988-01-18 1988-01-18 Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
YU8288A YU45837B (sh) 1988-01-18 1988-01-18 Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
DE3854387T DE3854387T2 (de) 1988-01-18 1988-12-28 Einschlusskomplex von Nicardipin oder seinem Hydrochlorid mit beta-Cyclodextrin, ein Verfahren zur Herstellung desselben und eine diesen enthaltende pharmazeutische Zubereitung mit verzögerter Wirkung.
EP88121797A EP0324982B1 (en) 1988-01-18 1988-12-28 Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for preparing the same and a sustained release pharmaceutical preparation containing the same
JP1006075A JPH0780849B2 (ja) 1988-01-18 1989-01-17 ニカルジピン又はその塩酸塩のβ―シクロデキストリン包接複合体及びそれを含有する医薬製剤
US07/298,151 US5079237A (en) 1988-01-18 1989-01-18 Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin and a sustained release pharmaceutical preparation containing the same
YU125289A YU45850B (sh) 1988-01-18 1989-06-19 Postopek za pripravo farmacevtskih pripravkovki vsebujejo nov inkluzijski kompleks nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU8288A YU45837B (sh) 1988-01-18 1988-01-18 Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom

Publications (2)

Publication Number Publication Date
YU8288A YU8288A (en) 1989-12-31
YU45837B true YU45837B (sh) 1992-07-20

Family

ID=25548253

Family Applications (1)

Application Number Title Priority Date Filing Date
YU8288A YU45837B (sh) 1988-01-18 1988-01-18 Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom

Country Status (6)

Country Link
US (1) US5079237A (sh)
EP (1) EP0324982B1 (sh)
JP (1) JPH0780849B2 (sh)
DE (1) DE3854387T2 (sh)
SI (1) SI8810082A8 (sh)
YU (1) YU45837B (sh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
TW282399B (sh) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
DE69301742T2 (de) * 1992-02-17 1996-08-14 Siegfried Ag Pharma Darreichungsformen mit verlaengerter Wirkstoffreigabe
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
BRPI0600636A (pt) * 2006-02-03 2007-10-30 Univ Minas Gerais processo para formulações de inibidores da enzima conversora de angiotensina e produto
MX2008013407A (es) 2006-04-18 2009-03-09 Ekr Therapeutics Inc Composiciones de bolo iv premezcladas, listas para uso y metodos de uso.
KR100900928B1 (ko) * 2007-06-05 2009-06-08 연세대학교 산학협력단 식물 스트레스 저항성을 증가시키는ＣａＲｍａ１Ｈ１유전자 및 상기 유전자가 도입된 형질전환식물체
KR100877188B1 (ko) * 2007-06-29 2009-01-07 한국원자력연구원 양성자 빔 처리에 의한 천연물 유래 미백용 화장료 조성물제조 방법
ES2332168B1 (es) * 2008-04-30 2010-10-27 Consejo Superior De Investigaciones Cientificas (Csic) (75%) Forma pseudopolimorfica de hidrocloruro de nicardipina, procedimiento para su preparacion y formulacion que la contiene.
JP5552400B2 (ja) * 2010-09-07 2014-07-16 東亜薬品株式会社 生薬類の苦味・不快味をマスキングした顆粒剤、及び口腔内速崩壊錠
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1455502A (en) * 1973-02-20 1976-11-10 Yamanouchi Pharma Co Ltd 1,4-dihydropyridine derivatives
JPS5486607A (en) * 1977-12-23 1979-07-10 Yoshinobu Nakai Solid pharmaceutical composition
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5948810B2 (ja) * 1980-03-22 1984-11-29 山之内製薬株式会社 ニカルジピン持続性製剤用組成物
JPS5634618A (en) * 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
AU558787B2 (en) * 1981-01-23 1987-02-12 Wellcome Foundation Limited, The Inclusion complexes of cyclodextrins and cardiac clycosides
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58213712A (ja) * 1982-06-07 1983-12-12 Nikken Kagaku Kk Ｐｐ−１４６６含有持続性製剤
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法
JPS61191623A (ja) * 1985-02-20 1986-08-26 Green Cross Corp:The 易吸収性医薬組成物
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
JP2603240B2 (ja) * 1987-03-09 1997-04-23 バイエル薬品株式会社 ジヒドロピリジン−ヒドロキシプロピルシクロデキストリン包接複合体

Also Published As

Publication number Publication date
DE3854387D1 (de) 1995-10-05
US5079237A (en) 1992-01-07
JPH02705A (ja) 1990-01-05
JPH0780849B2 (ja) 1995-08-30
YU8288A (en) 1989-12-31
EP0324982A1 (en) 1989-07-26
EP0324982B1 (en) 1995-08-30
SI8810082A8 (en) 1995-12-31
DE3854387T2 (de) 1996-04-11

Similar Documents

Publication Publication Date Title
YU45837B (sh) Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
ES2042725T3 (es) Procedimiento para preparar inhibidores de 5-alfa-estersa de esteroide.
GR3017282T3 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them.
IL103688A (en) Substituted biphenylpyridones their preparation and pharmaceutical compositions containing them
CA2033392A1 (en) A-nor-steroid-3-carboxylic acid derivatives
IT1096119B (it) Valvola perfezionata per la miscelazione di fluidi e per l'erogazione della miscela risultante
ES2104090T3 (es) Nuevas 3',5'-di-t-butil-4'-hidroxi-flavonas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
IL65163A (en) N-benzoyl-n'-benzylbispidine derivatives,their preparation and pharmaceutical compositions containing them
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
SE8405588D0 (sv) New compounds
ES2039292T3 (es) Derivados de piranobenzoxadiazol, preparacion de los mismos, utilizacion y compuestos que los comprenden.
PT83320B (en) Process for the preparation of cycloalkyl-substituted-4-aminophenyl derivatives and of pharmaceutical compositions containing
EP0267970A4 (en) NOVEL BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE.
ES2061478T3 (es) Derivados de teofilin-metil-ditiolano y teofilin-metil-ditianilo, un metodo para su preparacion, y composiciones farmaceuticas que los contienen.
IT8621874A0 (it) Procedimento di preparazione di additivi surbasati molto fluidi e a basicita' elevata, e composizione contenente i detti additivi.
HUT49326A (en) Process for producing sulfon derivatives as hydroxyalkilating agents
SE8704240D0 (sv) Analgesic preparations
DE3780757D1 (de) Antigestagene zur hemmung der uterinen prostaglandinsynthese.
DK61785D0 (da) 2-alkoxyaminosulfonylbenzensulfonylurinstofderivater, deres fremstilling og anvendelse som herbicider
DE3663664D1 (en) Compounds having antiplatelet aggregation activity, a process for the preparation thereof and pharmaceutical compositions containing them
ES8605247A1 (es) Procedimiento para la obtencion de arisulfonilguanidinas sustituidas
ES467886A1 (es) Procedimiento para la preparacion de derivados de acido oleanoico.
ES8703847A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinopirimidina
EP0257418A3 (en) Oxirane-pseudo-oligosaccharides, process for their synthesis, their use and pharmaceutical preparations